Cover Image
Market Research Report

Plaque Psoriasis: Epidemiology Forecast to 2027

Published by GlobalData Product code 778087
Published Content info 29 Pages
Delivery time: 1-2 business days
Price
Back to Top
Plaque Psoriasis: Epidemiology Forecast to 2027
Published: December 20, 2018 Content info: 29 Pages
Description

Epidemiologists forecast an increase in the one-year diagnosed prevalent cases of plaque psoriasis in the 7MM, from 16,030,747 cases in 2017 to 18,413,814 cases in 2027, at an AGR of 1.49% during the forecast period. Plaque psoriasis is not a life-threatening condition, but does have a significant impact on the patients' quality of life. Plaque psoriasis is often accompanied by one or more comorbidities, and frequently patients are stigmatized and excluded from social participation.

Plaque psoriasis is a chronic immune-mediated skin disease characterized by red, flaky patches that are itchy and sometimes painful. Psoriasis can occur on any area of the body such as the scalp, hands, and feet. There are several different types of psoriasis-plaque psoriasis, inverse psoriasis, guttate psoriasis, pustular psoriasis, erythrodermic psoriasis, and nail psoriasis-and they tend to occur in different areas of the body. Psoriatic plaques are formed due to an increased production of skin cells; normally the process to make and replace skin cells takes three to four weeks, but in psoriasis patients the process takes only a few days. The cause of plaque psoriasis is not known, but is thought to have a link to a problem in the immune system.

Plaque psoriasis, referred to as psoriasis in this report, is usually diagnosed by the look and distribution of plaques, and sometimes a small biopsy of the skin may be sent for analysis under the microscope. No cure for plaque psoriasis exists; however, treatments to ameliorate symptoms and appearance of skin are widely available. Other burdens associated with plaque psoriasis are socioeconomic ones, as patients can face elevated economic burden for treatment expenses and income lost due to disability, depending on the severity of the condition.

The "Plaque Psoriasis: Epidemiology Forecast to 2027", report provide an overview of the risk factors and global trends of plaque psoriasis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the one-year diagnosed prevalent cases of plaque psoriasis segmented by sex and age (beginning at 18 years and ending at ≥80 years) in these markets. Additionally the one-year diagnosed prevalent cases of plaque psoriasis are segmented into cases with psoriatic arthritis (PsA) and by severity.

Scope

  • The Plaque Psoriasis Epidemiology Report provides an overview of the risk factors and global trends of plaque psoriasis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report provides an overview of the risk factors, comorbidities, and global and historical trends for plaque psoriasis in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the one-year diagnosed prevalent cases of plaque psoriasis segmented by sex and age (beginning at 18 years and ending at ≥80 years) in these markets. Additionally the one-year diagnosed prevalent cases of plaque psoriasis are segmented into cases with psoriatic arthritis (PsA) and by severity.
  • The plaque psoriasis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Plaque Psoriasis Epidemiology report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global plaque psoriasis market.
  • Quantify patient populations in the global plaque psoriasis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for plaque psoriasis therapeutics in each of the markets covered.
  • Understand magnitude of plaque psoriasis segmentation by severity.
Table of Contents
Product Code: GDHCER198-18

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Plaque Psoriasis: Executive Summary 4

  • 2.1 Related Reports 5
  • 2.2 Upcoming Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 7
  • 3.3 Global and Historical Trends 8
  • 3.4 Forecast Methodology 9
    • 3.4.1 Sources 10
    • 3.4.2 Forecast Assumptions and Methods 12
  • 3.5 Epidemiological Forecast for Plaque Psoriasis (2017*2027) 16
    • 3.5.1 One-Year Diagnosed Prevalent Cases of Plaque Psoriasis 16
    • 3.5.2 Age-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis 18
    • 3.5.3 Sex-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis 19
    • 3.5.4 One-Year Diagnosed Prevalent Cases of Plaque Psoriasis by Severity 20
    • 3.5.5 One-Year Diagnosed Prevalent Cases of Plaque Psoriasis with PsA 21
  • 3.6 Discussion 21
    • 3.6.1 Epidemiological Forecast Insight 21
    • 3.6.2 Limitations of Analysis 22
    • 3.6.3 Strengths of Analysis 22

4 Appendix 23

  • 4.1 Bibliography 23
  • 4.2 Primary Research - Prescriber Survey 26
  • 4.3 About the Authors 27
    • 4.3.1 Epidemiologist 27
    • 4.3.2 Reviewers 27
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology 28
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy 28
  • 4.4 About GlobalData 29
  • 4.5 Contact Us 29
  • 4.6 Disclaimer 29

List of Tables

  • Table 1: Risk Factors and Comorbidities for Plaque Psoriasis 8
  • Table 2: High-Prescribing Physicians (non-KOLs) Surveyed for Psoriasis, By Country 26
  • Table 3: High-Prescribing Physicians (non-KOLs) Surveyed for Psoriatic Arthritis, By Country 26

List of Figures

  • Figure 1: 7MM, One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, Both Sexes, Ages ≥18 Years, 2017 and 2027 5
  • Figure 2: Age-Adjusted One-Year Diagnosed Prevalence of Plaque Psoriasis (%), Men and Women, Ages ≥18 Years, 2017 9
  • Figure 3: Sources Used and Not Used for One-Year Diagnosed Prevalent Cases of Plaque Psoriasis 10
  • Figure 4: Sources Used for One-Year Diagnosed Prevalent Cases of Plaque Psoriasis by Severity 11
  • Figure 5: Sources Used for One-Year Diagnosed Prevalent Cases of Plaque Psoriasis with PsA 12
  • Figure 6: One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, Ages ≥18 Years, 2017 17
  • Figure 7: Age-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, Ages ≥18 Years, 2017 18
  • Figure 8: Sex-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, Ages ≥18 Years, 2017 19
  • Figure 9: One-Year Diagnosed Prevalent Cases of Plaque Psoriasis by Severity, 7MM, Men and Women, Ages ≥18 Years, 2017 20
  • Figure 10: One-Year Diagnosed Prevalent Cases of Plaque Psoriasis with PsA, 7MM, Men and Women, Ages ≥18 Years, 2017 21
Back to Top